Drug intelligence / Profile preview

QLF32101

Development stage: Phase 1
Lead developer: Qilu Pharmaceutical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

QLF32101 is a bispecific antibody developed by Qilu Pharmaceutical for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It targets C-type lectin domain family 12 member A (CLEC12A/CLL1) on leukemic cells and T-cell surface glycoprotein CD3 epsilon chain (CD3) on T cells, functioning as a T cell engager to direct cytotoxic T lymphocytes against malignant cells. The drug is being evaluated in relapsed/refractory AML patients, with administration routes including intravenous and subcutaneous injection. As of 2024, it is in phase 1 clinical trials.

Targets

CLEC12ACD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on QLF32101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QLF32101.

Explore the full profile